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Abstract
Esophageal (EA) and esophagogastric junction (EGJA) adenocarcinoma have been steadily 
increasing in frequency in younger people, however the etiology of these cancers is poorly 
understood. We therefore investigated associations of body- mass index (BMI), cigarette smoking, 
alcohol consumption, gastroesophageal reflux, and use of non-steroidal anti-inflammatory drugs 
(NSAIDs) in relation to age-specific risks of EA and EGJA. We pooled individual participant data 
from eight population-based, case-control studies within the international Barrett’s and 
Esophageal Adenocarcinoma Consortium (BEACON). The analysis included 1,363 EA patients, 
1,472 EGJA patients, and 5,728 control participants. Multivariable logistic regression was used to 
estimate odds ratios (ORs) and 95% confidence intervals (CIs) for age-specific (<50, 50–59, 60–
69, ≥70 years) cancer outcomes, as well as interactions by age. BMI, smoking status and pack-
years, recurrent gastroesophageal reflux, and frequency of gastroesophageal reflux were positively 
associated with EA and EGJA in each age group. Early-onset EA (<50 years) had stronger 
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associations with recurrent gastroesophageal reflux (OR=8.06, 95%CI: 4.52, 14.37; 
Peffect modification=0.01) and BMI (ORBMI ≥30 vs. <25=4.19, 95%CI: 2.23, 7.87; 
Peffect modification=0.04), relative to older age groups. In contrast, inverse associations of NSAID 
use were strongest in the oldest age group (≥70 years), although this apparent difference was not 
statistically significant. Age-specific associations with EGJA showed similar, but slightly weaker 
patterns and no statistically significant differences by age were observed. Our study provides 
evidence that associations between obesity and gastroesophageal reflux are stronger among earlier 
onset EA cancers.
Keywords (MeSH terms)
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Introduction
Incidence of esophageal adenocarcinoma (EA) and esophagogastric junction 
adenocarcinoma (EGJA) has increased sharply in Western populations1, 2 among all age 
groups3–5. Survival has remained particularly poor, with five-year survival less than 20%6. 
A particularly disconcerting aspect is the growing proportion of advanced-stage tumors that 
occur at early-onset (< 50 years), as opposed to later-onset7–9, with most recent estimates 
from SEER indicating approximately 8.2% of EAs/EGJAs are diagnosed in US individuals 
less than 50 years of age. Understanding whether and how risk factor profiles vary by age 
could provide evidence-based information that may inform clinical practice, as well as 
provide etiologic insight.
A number of risk factors for EA and EGJA have been identified—irrespective of age at 
diagnosis. Increased risk is associated with male sex, white race, hiatal hernia10–12, 
gastroesophageal reflux10, 13, obesity14, and cigarette smoking15, 16. Inverse associations 
with usage of nonsteroidal anti-inflammatory drugs (NSAIDs)17 and moderate alcohol 
consumption18 have also been observed. Few studies have conducted age-specific risk factor 
analyses for EA and EGJA. One study suggested that obesity is more strongly associated 
with risk of EA among younger patients (<50 years)19 while another reported that obesity 
among patients was associated with younger median age at diagnosis20. Given the relative 
rarity of these malignancies prior studies have been limited in size, which has precluded 
detailed investigations across multiple age groups. Therefore, we leveraged the large sample 
size in the international Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON) 
and comprehensively evaluated risk factors by age at diagnosis, particularly focusing on 
early-onset (<50 years) disease.
Methods
Study Population
The BEACON consortium was formed in 2005 by an international group of 
investigators21–33. Consortium data consist of population-based case-control and cohort 
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studies of EA, EGJA and Barrett’s esophagus. The large total amount of consortium data 
enable the conduct of etiological studies of these conditions with excellent statistical power.
For this analysis, we included eight case-control studies that provided data from both EA 
and EGJA patients: the nationwide Australian Cancer Study (esophageal cancer 
component)32, Factors Influencing the Barrett’s Adenocarcinoma Relationship (FINBAR) 
Study21, nationwide Swedish Esophageal and Cardia Center Study (SECC)28, Larynx/
Esophagus/Oral cavity (LEO) Study29, Los Angeles County Multi-ethnic Study33, Nebraska 
Health Study II31, Population Health Study22, and the United States (US) Multi–Center 
Study27. Details about source populations, case definitions, recruitment procedures, 
participants, and study designs have been reported previously21–34.
The main outcomes of interest were age-specific groups of EA and EGJA patients; 
particularly early-onset disease (<50 years) given that risk factor profiles for this rarer group 
are poorly understood. Subjects were limited to those of white non-Hispanic ancestry, 
because of relatively small numbers of non-white or Hispanic patients (26 black, 89 
Hispanic, 42 other race or ethnic groups). The eight studies together provided 2,835 patients 
(1,363 EA, 1,472 EGJA) and 5,728 controls for analysis. Data acquisition and data pooling 
were approved by the Institutional Review Board or Research Ethics Committee of each 
participating institution included in the study.
Study Variables
Included studies provided information on age at diagnosis for case patients, age at interview 
for controls, sex, education, usual adult body mass index (BMI: weight divided by square of 
height [kg/m2]), alcohol consumption, cigarette smoking, and study center (for multi-center 
studies). Studies or their subsets also included information on reported heartburn and 
regurgitation21, 27, 28, 32, 33, and NSAID usage21, 27, 32, 33. Detailed information on exposure 
harmonization and detailed analyses of these risk factors has been reported previously for 
BMI14, alcohol consumption18, cigarette smoking16, 34, heartburn/regurgitation15, and 
NSAIDs use17. The categories for age at diagnosis were selected a priori based on 
convenient cut-points (<50, 50–59, 60–69, ≥70 years) for ease of interpretation.
Statistical Analysis
Primary exposure variables of interest included BMI, alcohol consumption, cigarette 
smoking, heartburn and regurgitation, and NSAID usage. Because of the small number of 
early-onset esophageal cancer diagnoses in each study (Table 1), we pooled data for our 
analysis, rather than using a 2-step meta-analytic approach as in most prior BEACON 
studies that have focused on a single exposure in relation to cancer diagnosed at any age and 
include larger case groups, such as BMI14, alcohol18, smoking34, or gastroesophageal 
reflux15. Multivariable logistic regression models were used to estimate odds ratios (ORs) 
and their 95% confidence intervals (CIs) for the association between each primary exposure 
variable and each outcome (EA or EGJA) stratified by age (diagnosis for cases, interview 
for controls; <50, 50–59, 60–69, ≥70 years). Covariates included in the multivariable 
logistic regression models (if not assessed as primary exposure variables) included age 
(continuous), sex, study, study-center (for multicenter studies), education (< or ≥ high 
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school), BMI (continuous), ever regular consumption of alcohol, and smoking status (never, 
current, former), as these variables are either of primary interest or known to be associated 
with these malignancies and thus potential confounders35.
As previously noted, a subset of studies also included information on the following risk 
factors: heartburn, regurgitation or both as recurrent symptoms (≥ weekly frequency: yes/no) 
and frequency of heartburn, regurgitation or both (never, <monthly, monthly to <weekly, 
weekly to <daily, ≥daily) and regular NSAID use (ever/never; including aspirin usage and 
non-aspirin NSAID usage).
To assess effect modification by age group, we used the likelihood-ratio statistic to compare 
nested models of the age-adjusted main-effect data (i.e., not stratified by age) with a model 
that also included main-effect exposure-age category interaction terms (<50, 50–59, 60–69, 
≥70 years; 3df). All analyses were performed using Stata software version 13. All statistical 
tests were two–sided and P-values less than 0.05 were considered to be statistically 
significant.
Results
In total, data from 1,363 EA and 1,472 EGJA case patients were available for the analysis 
(Table 1). Among these subjects, 125 EA and 174 EGJA patients had been diagnosed at <50 
years of age (10.5%), 314 EA and 334 EGJA diagnosed at 50–59 years of age (22.9%), 473 
EA and 526 EGJA diagnosed at 60–69 years of age (35.2%), and 451 EA and 438 EGJA 
patients diagnosed at ≥70 years of age (31.4%). In total, 5,728 population controls—
including 790 aged <50 years, 1,286 aged 50–59 years, 1,936 aged 60–69 years, and 1,716 
aged ≥70 years—were available for comparison (Table 1). Study participant characteristics 
by age at diagnosis/interview are shown in Supplementary Table 1.
The overall and age-specific risk factor profiles of EA and EGJA are provided in Tables 2 
and 3. Overall we observed an increased risk of EA and EGJA with increasing BMI, 
whereas alcohol consumption categories up to 3–5 drinks per day, but not more, were 
inversely associated, each compared with the 0 drinks per day category. Current or former 
cigarette smoking status were each positively associated with increased risk of both EA and 
EGJA, and we observed a trend of increasing risks with increasing cumulative exposure to 
tobacco smoke (pack-years). Recurrent heartburn and/or recurrent regurgitation, and greater 
frequency of symptoms were associated with increased risk of both cancers. Lastly, we 
observed inverse associations with use of NSAIDs and aspirin, and a modest inverse 
association with non-aspirin NSAID usage with EA. In contrast, associations between 
NSAID use and EGJA were mostly null. These results are similar to individual exposures 
investigated in prior BEACON studies14, 15, 17, 18, 34.
We next evaluated age-specific associations of each exposure in relation to EA. Obesity 
(BMI ≥30) was most strongly associated with early-onset EA (OR=4.19, 95%CI: 2.23, 
7.87), with significant differences across age groups (Peffect modification=0.042). The 
magnitude of the association was higher in early-onset EA than in later-onset patients. ORs 
for the other age categories ranged between 2.6–2.8. When we limited our analysis to studies 
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including reflux variables and further adjusted models by recurrent reflux, little difference 
was seen in the association between BMI and EA in the youngest age group (Supplemental 
Table 3: OR: 2.1 vs OR: 2.3) and age remained an effect modifier (Peffect modification=0.002).
Alcohol consumption and number of drinks per day showed little to no associations with 
risk of EA among age groups <50, 50–59, and 60–69 years. However, for the age group ≥70 
years the inverse association for regular drinking was stronger and gained nominal statistical 
significance (OR 0.62, 95%CI: 0.45, 0.85). Similar findings were found for frequency of 
alcohol consumption, up to and including the 5–<7 drinks per day category. However, tests 
for effect modification by age were not statistically significant for either ever regularly 
consuming alcohol (Peffect modification=0.17) or for frequency of alcohol consumption 
(Peffect modification=0.33).
Current and former cigarette smokers were at increased risk of EA in each age group 
assessed compared with never-smokers. ORs ranged between 1.81 and 3.75 for former and 
current smokers. Effect modification by age was observed (P=0.028), yet no obvious linear 
pattern across age groups was seen. Associations were strongest for 50–59 year olds and 
weakest for 60–69 year olds, and these differences persisted when pack-years of cigarette 
smoking was included in the model, albeit the P value for effect modification was slightly 
attenuated and not statistically significant (P=0.073).
We observed statistically significant positive associations between recurrent 
gastroesophageal reflux variables (≥ weekly symptoms) and EA risk for all age groups. The 
strongest associations were observed for early-onset EA, with ORs ranging from 6.62 to 
8.06 and age was consistently a significant effect modifier (Peffect modification=0.02–0.04). In 
contrast, associations between EA and frequency of heartburn and/or regurgitation 
symptoms were similar across each age groups (Peffect modification=0.16–0.57).
Regular use of NSAIDs and aspirin were inversely associated with EA for the age group ≥ 
70 years. For all other age groups assessed, weaker inverse associations of these exposures 
with EA risk were seen, although most of them were not statistically significant and neither 
were their tests effect modifications by age (P=0.09–0.12). No substantial differences for 
regular use of non–aspirin NSAIDs were seen by age group and were not associated.
Age-specific analyses of EGJA (Table 3) provided generally similar results to those 
observed for EA (Table 2). Age-specific associations of BMI, alcohol, and gastroesophageal 
reflux exposures in relation to EGJA were slightly attenuated when compared with those for 
EA, but were similar in patterns and direction. However, none of these apparent differences 
were statistically significant. Inverse associations were seen between users of non-aspirin 
NSAIDs and EGJA in older age groups (60–69 and ≥ 70) compared with non-users. 
However, unlike the EA analysis, no associations were observed with regular usage of 
aspirin.
Discussion
In this large pooled analysis of eight population-based case-control studies we found that 
recurrent heartburn/regurgitation and obesity were appreciably stronger risk factors for 
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early-onset EA relative to older age categories. Conversely, low/moderate alcohol 
consumption and use of aspirin and NSAIDs were inversely associated with late-onset EA, 
although effect modifications of these associations by age were not significant. Age-specific 
associations with EGJA showed similar, but slightly weaker patterns and no statistically 
significant differences by age were observed.
To our knowledge this is the first pooled analysis aimed to evaluate and compare age-
specific risk factor profiles for EGJA and one of only a few for EA. In a prior study of age-
specific risk factors of EA (cases: n=356), the authors also found that obesity was associated 
with a younger age at cancer diagnosis20. Our pooled analysis corroborates that finding and 
provides detailed investigations of the major risk factors across multiple age groups. 
Although the rise in EA incidence predates the rise in obesity36, it is still possible that 
obesity is implicated in more recent increases in EA incidence; as evidenced by the strong 
associations with BE and EA observed in prior BEACON analyses37, 38 and other studies39.
The predominant mechanism by which central adiposity is proposed to increase risk of 
esophageal cancer is by disrupting the integrity of the lower esophageal sphincter; leading to 
increased propensity for gastroesophageal reflux40. Independent of the “mechanical effect” 
of central adiposity on cancer risk, proinflammatory effects of excess adipose tissue may 
increase risk of EA via systemic proinflammatory effects14, 40, 41. In this study we also 
observed some evidence for an effect of obesity on risk of EA that is independent of reflux 
symptoms.
No prior study, independent of the studies contributing to this pooled analysis, has 
investigated age-specific associations between recurrent heartburn/regurgitation and risk of 
EA. Reflux increases secretion of numerous proinflammatory cytokines such as IL-6 and 
TNF-α and reactive oxygen species42–44. As a recognized hallmark of cancer45, 
inflammation induced by reflux is likely to contribute substantially to the development and 
progression of esophageal adenocarcinoma46. Among a subset of the EA patients included 
in this study, four SNPs in three apoptosis genes (BCL2, CASP8, and TNFRSF10A) were 
previously identified as significantly associated with early-onset EA (≤55 vs >55 years)9. 
Taken together, one possible explanation for our results is that patients diagnosed with EA at 
younger ages may have increased likelihood of genetic susceptibility to the deleterious 
effect of reflux, perhaps having decreased ability to expunge damaged cells via apoptosis. 
This process could lead to the accumulation of oncogenic mutations in the esophageal cell 
population, heightening the risk of early-onset EA.
An important strength of our study was the availability of individual participant data from 
eight population-based, case-control studies, which provided sufficient case numbers 
required to identify risk factor profiles for early and late-onset disease and to assess effect 
modification by age. Our exposure variables are believed to have a high degree of reliability, 
since each was constructed using a unified approach across studies and each exposure in 
relation to EA and EGJA has been examined and published. Our overall results corroborate 
the findings of these prior studies14, 15, 17, 18, 34 and provide confidence in our statistical 
approach.
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However, several limitations of our analysis should be considered. We have not assessed 
heritability or genetic factors. These factors could induce differential residual confounding 
by age at diagnosis, possibly contributing to the effect modification by age effects that we 
observed47–50. The categories for age at diagnosis were selected a priori based on 
convenient cut-points for ease of interpretation, however, similar trends were observed when 
age-at-diagnosis categories were based on quartiles of age among controls (data not shown). 
It is important to note that our analysis includes self-reported symptoms of heartburn and 
regurgitation, yet reflux exposures can occur without apparent symptoms. Symptoms have 
been shown to correlate with greater severity of acid reflux exposure51; nonetheless our 
results may only apply to people with symptomatic heartburn or regurgitation.
Overall, this study confirms that smoking, obesity, recurrent or frequent heartburn/
regurgitation are all associated with increased risk of EA and EGJA across all ages studied. 
In addition, we found evidence that recurrent heartburn/regurgitation and obesity are more 
strongly associated with risk of early-onset EA, compared with older age groups. 
Understanding the mechanisms through which obesity and reflux confer increased risks of 
esophageal cancer at younger ages might yield important insights for prevention and control 
of this cancer. Moreover, as the clinical community aims to incorporate more evidence-
based health decisions, it is prudent that age-specific risk estimates be considered.
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Incidence in esophageal adenocarcinoma has increased sharply among all age groups; 
however one disconcerting trend is the increasing proportion of advanced-stage tumors 
occurring at younger (< 50 years) as opposed to older ages. The relative rarity of these 
malignancies has precluded prior studies from assessing risk factors across age groups. 
Pooling data from 8 case-control studies we found that recurrent heartburn/regurgitation 
and obesity were appreciably stronger risk factors for early-onset EA relative to older 
age-categories.
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